Change from Baseline for Clinical Safety Laboratory Parameters;Number of Participants with One or More Adverse Events of Special Interest (AESIs) Including Potentially Immune-Mediated Medical Condition (PIMMCs), Medically Attended Adverse Events (MAAEs) and New Onset Chronic Medical Condition (NOCMCs);Number of Participants with One or More Serious Adverse Events;Number of Participants with One or More Solicited Local Reactogenicity Signs and Symptoms;Number of Participants with One or More Solicited Systemic Reactogenicity Signs and Symptoms;Number of Participants with One or More Unsolicited Adverse Events (AEs)

Change from Baseline for Clinical Safety Laboratory Parameters;Number of Participants with One or More Adverse Events of Special Interest (AESIs) Including Potentially Immune-Mediated Medical Condition (PIMMCs), Medically Attended Adverse Events (MAAEs) and New Onset Chronic Medical Condition (NOCMCs);Number of Participants with One or More Serious Adverse Events;Number of Participants with One or More Solicited Local Reactogenicity Signs and Symptoms;Number of Participants with One or More Solicited Systemic Reactogenicity Signs and Symptoms;Number of Participants with One or More Unsolicited Adverse Events (AEs)